The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.
New drug delivery methods are seen by some pharmaceutical giants as a crucial growth generator and new innovations are spreading across the healthcare sector. Many experts believe that personalized medicine is the future of healthcare and customized drug delivery has the potential to drastically change the way value is assessed and compensated in the U.S. healthcare system.
RBCC is working hard to capitalize on the changing drug-delivery paradigm by partnering with key players in the field. The company is now in talks with an emerging company that owns technology with the potential to enable selective site-specific delivery allowing for lower drug concentrations and greatly reducing the risk of drug toxicity. In addition to helping millions of patients struggling with chronic conditions this bold new technology can also extend the patent life cycles of drugs giving potential pharmaceutical partners a tremendous market advantage.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY) Biogen Idec Inc. (NASDAQ: BIIB) Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences LLC is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations.
